Greasing the wheels of Aβ clearance in Alzheimer's Disease: The role of lipids and apolipoprotein e

BioFactors

Volumn 35, Issue 3, 2009, Pages 239-248

  Fan, Jianjia ^a   Donkin, James ^a   Wellington, Cheryl ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ABCA 1; Alzheimer's disease; Apolipoprotein E; Liver XReceptor

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; INSULINASE; LIPID; LIVER X RECEPTOR; MEMBRANE METALLOENDOPEPTIDASE; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PHOSPHOLIPID; SIMVASTATIN; TRANSCRIPTION FACTOR;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN; BRAIN BLOOD VESSEL; CATALYSIS; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; COGNITION; ENCEPHALITIS; GENETIC DISORDER; GENETICS; HOMEOSTASIS; HUMAN; IN VIVO STUDY; INTROSPECTION; MENTAL PERFORMANCE; NERVE CELL; NONHUMAN; PATHOGENESIS; PHOSPHOLIPID TRANSFER; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN TRANSPORT; REVIEW; ANIMAL; BIOLOGICAL MODEL; LIPID METABOLISM; METABOLISM; PHYSIOLOGY;

MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEINS E; HUMANS; LIPID METABOLISM; LIPIDS; MODELS, BIOLOGICAL;

EID: 69149109381     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.37     Document Type: Review

References (120)

1. Price, D. L., Tanzi, R. E., Borchelt, D. R., and Sisodia, S. S. (1998) Alzheimer's disease: genetic studies and transgenic models. Ann. Rev. Genet. 32, 461-493.
2. McKhann, G., Drachman, D., Folstein, M., Katzmann, R., Price, D., and Stadlan, E. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the department of health and human services task force on Alzheimer's disease. Neurology 34, 939-944.
3. Morris, J. C. (1997) Clinical assessment of Alzheimer's disease. Neurology (Suppl) 49, S7-S10.
4. Selkoe, D. J. (2001) Clearing the brain's amyloid cobwebs. Neuron 32, 177-180.
5. Zlokovic, B. V., Yamada, S., Holtzman, D., Ghiso, J., and Frangione, B. (2000) Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat. Med. 6, 718-719.
6. Tanzi, R., Moir, R., and Wagner, S. (2004) Clearance of Alzheimer's Abeta peptide: the roads to perdition. Neuron 43:605-608.
7. Zlokovic, B. V. (2008) New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 5, 409-414.
8. Jick, H., Zornberg, G. L., Jick, S. S., Sashadri, S., and Drachman, D. A. (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
9. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., and Siegel, G. (2000) Decreased prevalence of Alzheimer disease associated with 3- hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443.
10. Green, R. C., McNagny, S. E., Jayakumar, P., Cupples, L. A., Benke, K., Farrer, L. A., and MIRAGE study group. (2006) Statin use and the risk of Alzheimer's disease: the MIRAGE study. Alzheimers Dement. 2, 96-103.
11. Wolozin, B., Wang, S. W., Li, N. C., Lee, A., Lee, T. A., and Kazis, L. E. (2007) Simvastatin is associated with a reduced indicidence of dementia and Parkinson's disease. BMC Med. 19, 20-48.
12. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lütjohann, D., Keller, P., Runz, H., Kühl, S., Bertsch, T., von Bergmann, K., Hennerici, M., Beyreuther, K., and Hartmann, T. (2001) Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Ab42 and Ab40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 98, 5856-5861.
13. Refolo, L. M., Pappolla, M. A., LaFrancois, J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., Tint, G. S., Wang, R., Mercken, M., Petanceska, S. S., and Duff, K. E. (2001) A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's Disease. Neurobiol. Dis. 8, 890-899.
14. Kojro, E., Gimple, G., Lammich, S., März, W., and Fahrenholz, F. (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl. Acad. Sci. USA. 98, 5815-5820.
15. Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dottie, C. G., and Simons, K. (1998) Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA. 95, 6460-6464.
16. Bodovitz, S. and Klein, W. L. (1996) Cholesterol modulates a-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271, 4436-4440.
17. Ehehalt, R., Keller, P., Haass, C., Thiele, C., and Simons, K. (2003) Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell. Biol. 160, 113-123.
18. Vega, G. L., Weiner, M. F., Lipton, A. M., von Bergmann, K., Lutjohann, D., Moore, C., and Svetlik, D. (2003) Reduction in levels of 24Shydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch. Neurol. 60, 510-515.
19. Locatelli, S., Lütjohann, D., Schmidt, H. H. J., Carsten, O., Beiseiegel, U., and von Bergmann, K. (2002) Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia. Arch. Neurol. 59, 213-216.
20. Simons, M., Schwärzler, F., Lutjohann, D., von Bergmann, K., Beyreuther, K., Dichgans, J., Wormstall, H., Hartmann, T., and Schulz, J. B. (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled double blind trial. Ann. Neurol. 52, 346-350.
21. Hoglund, K., Thelen, K. M., Syversen, S., Sjogren, M., von Bergmann, K., Wallin, A., Vanmechelen, E., Vanderstichele, H., Lutjohann, D., and Blennow, K. (2005) The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 19, 256-265.
22. Rockwood, K. (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59, 223-227.
23. Sjogren, M., Gustafsson, K., Syversen, S., Olsson, A., Edmann, A., Davidsson, P., Wallin, A., and Blennow, K. (2003) Treatment with simvastatin in patients with Alzheimer's disease lowers both alphaand beta-cleaved amyloid precursor protein. Dement. Geriatr. Cogn. Disord. 16, 25-30.
24. Buxbaum, J. D., Cullen, E. I., and Friedhoff, L. T. (2002) Pharmacological concentrations of the HMG-CoA reducatase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid in vitro and in patients. Front. Biosci. 7, 50-59.
25. Hajjar, I., Schumpert, J., Hirth, V., Wieland, D., and Eleazer, G. P. (2002) The impact of the use of statins on the prevalance of dementia and the progression of cognitive impairment. J. Gerontol. A. Biol. Sci. Med. Sci. 57, M414-M418.
26. Rodriguez, E. G., Dodge, H. H., Birzescu, M. A., Stoehr, G. P., and Ganguli, M. (2002) Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J. Am. Geriatr. Soc. 50, 1852-1856.
27. Yaffe, K., Barret-Connor, E., Lin, F., and Grady, D. (2002) Serum lipoprotein levels, stain use, and cognitive function in older women. Arch. Neurol. 59, 378-384.
28. Sparks, D. L., Sabbagh, M. N., Connor, D. J., Lopez, J., Launer, L. J., Browne, P., Wasser, D., Johnson-Traver, S., Lochhead, J., and Ziolwolski, C. (2005) Atorvastatin for the treatment of mild to moderate Alzheimer Disease. Arch. Neurol. 62, 753-757.
29. Zandi, P. P., Sparks, D. L., Khachaturian, A. S., Tschanz, J., Norton, M., Steinberg, M., Welsh-Bohmer, K. A., and Breitner, J. C. S. (2005) Do statins reduce risk of incident dementia and Alzheimer's Disease?: the Cache County Study. Arch. Gen. Psychiatry. 62, 217-224.
30. Santanello, N. C., Barber, B. L., Applegate, W. B., Elam, J., Curtis, C., Hunninghake, D. B., and Gordon, D. J. (1997) Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Porgram (CRISP) Pilot Study. J. Am. Geriatr. Soc. 45, 8-14.
31. Heart Protection Study Collaborative Group. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22.
32. Shepherd, J., Blauw, G. J., Murphy, M. B. E. L. E., Bollen, M., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., Kamper, A. M., Macfarlane, P. W., Meinders, A. E., Norrie, J., Packard, C. J., Perry, I. J., Stott, D. J., Sweeney, B. J., Twomey, C., Westendorp, R. G. J., and PROSPER Study Group. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630.
33. Li, G., Higdon, R., Kukull, W. A., Peskind, E., Van Valen Moore, K., Tsuang, D., van Belle, G., McCormick, W., Bowen, J. D., Teri, L., Schellenberg, G. D., and Larson, E. B. (2004) Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63, 1624-1628.
34. Dietschy, J. M. and Turley, S. D. (2001) Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12, 105-112.
35. Ladu, M. J., Reardon, C., Van Eldik, L., Fagan, A. M., Bu, G., Holtzmann, D., and Getz, G. S. (2000) Lipoproteins in the central nervous system. Ann. N Y Acad. Sci. 903, 167-175.
36. Pitas, R. E., Boyles, J. K., Lee, S. H., Hui, D., and Weisgraber, K. H. (1987) Lipoproteins and their receptors in the central nervous system. J. Biol. Chem. 262, 14352-14360.
37. Beffert, U., Danik, M., Krzywkowski, P., Ramassamy, C., Berrada, F., and Poirier, J. (1998) The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res. Brain Res. Rev. 27, 119-142
38. Dietschy, J. M. and Turley, S. D. (2004) Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45, 1375-1397.
39. Ignatius, M. J., Gebicke-Harter, P. J., Pitas, R. E., and Shooter, E. M. (1987) Apolipoprotein E in nerve injury and repair. Prog. Brain. Res. 71, 177-184.
40. Poirier, J. (1994) Apolipoprotein E in animal models of CNS injury and Alzheimer's disease. Trends. Neurosci. 17, 525-530.
41. Strittmatter, W. J. and Roses, A. D. (1995) Apolipoprotein E and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 92, 4725-4727.
42. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., and Pericak-Vance, M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
43. Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., and Pericak-Vance, M. A. (1994) Protective effect of apolipoprotein E type 2 for late onset Alzheimer disease. Nat. Genet. 7, 180-184.
44. Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L-M., Salveson, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., and Rose, A. D. (1993) Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90, 8098-8102.
45. Bales, K. R., Verina, T., Dodel, R., Du, Y., Alsteil, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., Piccardo, P., Ghetti, B., and Paul, S. M. (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17, 263-264.
46. Holtzman, D. M., Fagan, A. M., Mackey, B., Tenkova, T., Sartorius, L., Paul, S. M., Bales, K., Ashe, K. H., Irizarry, M. C., and Hyman, B. T. (2000) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47, 739-747. (Pubitemid 30390194)
47. Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., Fishman, C. E., DeLong, C. A., Piccardo, P., Petegnief, V., Ghetti, B., and Paul, S. M. (1999) Apolipoprotein E is essential for amyloid deposition in the APP (V717F) transgenic mouse model of Alzheimer's Disease. Proc. Natl. Acad. Sci. USA. 96, 15233-15238.
48. Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., and Paul, S. M. (1999) Expression of human apolipoprotein E reduces amyloid-b deposition in a mouse model of Alzheimer's Disease. J. Clin. Invest. 103, R15-R21.
49. Costa, D. A., Nilsson, L. N., Bales, K. R., Paul, S. M., and Potter, H. (2004) Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous Abeta deposition, in an AbetaPP/PS double transgenic mouse model of Alzheimer's disease. J. Alzheimers. Dis. 6, 509-514.
50. Irizarry, M. C., Rebeck, G. W., Cheung, B., Bales, K., Paul, S. M., Holzman, D., and Hyman, B. T. (2000) Modulation of Ab deposition in APP transgenic mice by an apolipoprotein E null background. Ann. NY Acad. Sci. 920, 171-178.
51. Fryer, J. D., DeMattos, R. B., McCormick, L. M., O'Dell, M. A., Spinner, M. L., Bales, K. R., Paul, S. M., Sullivan, P. M., Parsadanian, M., Bu, G., and Holtzman, D. M. (2005) The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 280, 25754-25759.
52. Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J. F., Naus, K. E., McIsaac, S. A., Parkinson, P. F., Chan, J. Y., Tansley, G. H., Hayden, M. R., Poirier, J., Van Nostrand, W. E., and Wellington, C. L. (2005) The absence of ABCA1 decreases soluble apoE levels but does not diminish amyloid deposition in two murine models of Alzheimer's Disease. J. Biol. Chem. 280, 43243-43256.
53. Koldamova, R., Staufenbiel, M., and Lefterov, I. (2005) Lack of ABCA1 considerably decreased brain apoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280, 43224-43235.
54. Wahrle, S., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., Paul, S. M., and Holtzman, D. M. (2005) Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280, 43236-43242. (Pubitemid 43049290)
55. Burns, M. P., Vardanian, L., Pajoohesh-Gangi, A., Wang, L., Cooper, M., Harris, D. C., Duff, K., and Rebeck, G. W. (2006) The effects of ABCA1 on cholesterol efflux and Aβ levels in vitro and in vivo. J. Neurochem. 98, 792-800.
56. Riddell, D. R., Zhou, H., Atchison, K., Warwick, H. K., Jefferson, J., Xu, L., Aschmies, S., Kirksey, Y., Hu, Y., Wagner, E., Parratt, A., Xu, J., Li, Z., Zaleska, M. M., Jacobson, J. S., Pangalos, M. N., and Reinhart, P. H. (2008) Impact of apolipoprotein E (apoE) polymorphism on brain apoE levels. Neurobiol. Dis. 28, 11445-11453.
57. Hatters, D. M., Budamagunta, M. S., Voss, J. C., and Weisgraber, K. H. (2005) Modulation of apolipoprotein E structure by domain interaction. J. Biol. Chem. 280, 34288-34295.
58. Ramaswamy, G., Xu, Q., Huang, Y., and Weisgraber, K. H. (2005) Effect of domain interaction on apolipoprotein E levels in mouse brain. J. Neurosci. 25, 10658-10663.
59. Zhong, N., Scearce-Levie, K., Ramaswamy, G., and Weisgraber, K. H. (2008) Apolipoprotein E4 domain interaction: synaptic and cognitive deficits in mice. Alzheimer's. Demen. 4, 179-192.
60. Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., and Paul, S. M. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 97, 2892-2897.
61. Carter, D. B., Dunn, E., McKinley, D. D., Stratman, N. C., Boyle, T. P., Kuiper, S. L., Oostveen, J. A., Weaver, R. J., Boller, J. A., and Gurney, M. E. (2001) Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain. Ann. Neurol. 50, 468-475.
62. Buttini, M., Yu, G. Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M., and Mucke, L. (2002) Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 22, 10539-10548.
63. Dodart, J. C., Marr, R. A., Koistinaho, M., Gregersen, B. M., Malkani, S., Verma, I. M., and Paul, S. M. (2005) Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 102, 1211-1216.
64. Xu, F., Vitek, M. P., Colton, C. A., Previti, M. L., Gharkholonarehe, N., Davis, J., and Van Nostrand, W. E. (2008) Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. J. Neurosci. 28, 5312-5320.
65. Burns, M. P., Noble, W. J., Olm, V., Gaynor, K., Casey, E., LaFrancois, J., Wang, L., and Duff, K. (2003) Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain. Res. Mol. Brain. Res. 110, 119-125.
66. Burns, M. P., Igbavboa, U., Wang, L., Wood, W. G., and Duff, K. (2006) Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. Neuromol. Med. 8, 319-328.
67. Ladu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G. S., and Frail, D. E. (1994) Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 269, 23403-23406.
68. Tokuda, T., Calero, M., Matsubara, E., Vidal, R., Kumar, A., Permanne, B., Zlokovic, B., Smith, J. D., Ladu, M. J., Rostagno, A., and Ghiso, J. (2000) Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides. Biochem. J. 348, 359-365.
69. Wisniewski, T., Castano, E. M., Golabek, A., Vogel, T., and Frangione, B. (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145, 1030-1035.
70. Castano, E. M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R. A., Soto, C., and Frangione, B. (1995) Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 306 (Pt 2), 599-604
71. Cam, J. A. and Bu, G. (2006) Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol. Neurodegen. 1, 8.
72. Ye, S., Huang, Y., Mullendorff, K., Dong, L., Giedt, G., Meng, E. C., Cohen, F. E., Kuntz, I. D., Weisgraber, K. H., and Mahley, R. W. (2005) Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. USA. 102, 18700-18705.
73. Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., and Husemann, J. (2003) Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 9, 453-457.
74. Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., and Paul, S. M. (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat. Med. 10, 719-726.
75. Cole, G. M. and Ard, M. D. (2000) Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein. Microsc. Res Tech. 50, 316-324.
76. Zlokovic, B. V. (2004) Clearing amyloid through the blood-brain barrier. J. Neurochem. 89, 807-811.
77. Bell, R. D., Sagaare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., and Zlokovic, B. V. (2006) Transport pathways for clearance of human Alzheimer's amyloid b-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood. Flow. Metab. 27, 909-918.
78. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., and Zlokovic, B. V. (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118, 4002-4013.
79. Hirsch-Reinshagen, V., Zhou, S., Burgess, B. L., Bernier, L., McIsaac, S. A., Chan, J. Y., Tansley, G. H., Cohn, J. S., Hayden, M. R., and Wellington, C. L. (2004) Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 279, 41197-41207.
80. Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., and Holtzman, D. M. (2004) ABCA1 is required for normal CNS apoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279, 40987-40993.
81. Ladu, M. J., Gilligan, S. M., Lukens, J. R., Cabana, V. G., Reardon, C. A., Van Eldik, L. J., and Holtzman, D. A. (1998) Nascent astrocyte particles differ from lipoproteins in CSF. J. Neurochem. 70, 2070-2081.
82. Burgess, B. L., Parkinson, P. F., Racke, M. M., Hirsch-Reinshagen, V., Fan, J., Wong, C., Stukas, S., Theroux, L., Chan, J. Y., Donkin, J., Wilkinson, A., Balik, D., Christie, B., Poirier, J., Lutjohann, D., DeMattos, R. B., and Wellington, C. L. (2008) ABCG1 influences brain cholesterol synthesis but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J. Lipid. Res. 49, 1254-1267.
83. Wahrle, S. E., Jiang, H., Parsadanian, M., Kim, J., Li, A., Knoten, A., Jain, S., Hirsch-Reinshagen, V., Wellington, C. L., Bales, K. R., Paul, S. M., and Holtzman, D. M. (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118, 671-682.
84. Hirsch-Reinshagen, V., Chan, J. Y., Wilkinson, A., Tanaka, T., Fan, J., Ou, G., Maia, L. F., Singaraja, R., Hayden, M. R., and Wellington, C. L. (2007) Physiologically regulated ABCA1 does not reduce amyloid burden or beta-amyloid levels in vivo. J. Lipid. Res. 48, 914-923.
85. Jiang, Q., Lee, C. Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., Richardson, J. C., Smith, J. D., Comery, T. A., Riddell, D., Holtzman, D. M., Tontonoz, P., and Landreth, G. E. (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58, 681-693.
86. Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H. J., Hama, E., Sekine-Aizawa, Y., and Saido, T. C. (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6, 143-150.
87. Rogers, J., Strohmeyer, R., Kovelowski, C. J., and Li, R. (2002) Microglia and inflammatory mechanisms in the clearance of amyloid b peptide. Glia 40, 260-269.
88. Kurochkin, I. V. and Goto, S. (1994) Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345, 33-37.
89. Qiu, W. Q., Walsh, D. M., We, Z., Vekrellis, K., Zhang, J., Pidisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., and Selkoe, D. J. (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273, 32730-32738.
90. Dolev, I. and Michaelson, D. M. (2004) A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc. Natl. Acad. Sci. USA. 101, 13909-13914.
91. Hemming, M. L., Patterson, M., Reske-Nielsen, C., Lin, L., Isacson, O., and Selkoe, D. J. (2007) Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS. Med. 4, e262.
92. Deane, R., Wu, Z., Sagare, A., Davis, J., Du, Y. S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., Spijkers, P., Lenting, P. J., Van Nostrand, W. E., and Zlokovic, B. V. (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344
93. Beaven, S. W. and Tontonoz, P. (2006) Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 57, 313-329.
94. Kalaany, N. Y. and Mangelsdorf, D. J. (2006) LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68, 159-191.
95. Willy, J. P., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., and Mangelsdorf, D. J. (1995) LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes. Dev. 9, 1033-1045.
96. Whitney, K. D., Watson, M. A., Collins, J. L., Benson, W. G., Stone, T. M., Numerick, M. J., Tippin, T. K., Wilson, J. G., Winegar, D. A., and Kliewer, S. A. (2002) Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol. Endocrinol. 16, 1378-1385.
97. Claudel, T., Leibowitz, M. D., Fievet, C., Tailleux, A., Wagner, B., and Repa, J. J. (2001) Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. USA. 98, 2610-2615.
98. Repa, J. J., Berge, K. E., Pomajzl, C., Richardson, J. A., Hobbs, H., and Mangelsdorf, D. J. (2002) Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors α and β. J. Biol. Chem. 277, 18793-18800.
99. Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., and Mangelsdorf, D. J. (1996) An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383, 728-731.
100. Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., and Wilson, T. M. (1997) Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272, 3137-3140.
101. Lin, Y. Y. and Smith, L. L. (1974) Sterol metabolism. 28. Biosynthesis and accumulation of cholest-5-ene-3beta, 24-diol (cerebrosterol) in developing rat brain. Biochim. Biophys. Acta. 348, 189-196.
102. Bjorkhem, I., Andersson, O., Diczfalusy, U., Sevastik, B., Xiu, R. J., Duan, C., and Lund, E. (1994) Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc. Natl. Acad. Sci. U.S.A. 91, 8592-8596.
103. Lund, E. G., Kerr, T. A., Sakai, J., Li, W. P., and Russell, D. W. (1998) cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that syntehsize a potent oxysterol regulator of lipid metabolism. J. Biol. Chem. 273, 34316-34327.
104. Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., Lustig, K. D., and Shan, B. (2000) Role of LXRs in control of lipogenesis. Genes. Dev. 14, 2831-2838.
105. Lund, E. G., Menke, J. G., and Sparrow, C. P. (2003) Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 1169-1177
106. Kapur, N. K., Ashen, D., and Blumenthal, R. S. (2008) High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. Vasc. Health Risk Manag. 4, 39-57.
107. Repa, J. J. and Mangelsdorf, D. J. (2000) The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Ann. Rev. Cell. Dev. Biol. 16, 459-481.
108. Fujiyoshi, M., Ohtsuki, S., Hori, S., Tachikawa, M., and Terasaki, T. (2007) 24S-hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression. J. Neurochem. 100, 968-978.
109. Liang, Y., Lin, S., Beyer, T. P., Zhang, Y., Wu, X., Bales, K. R., DeMattos, R. B., May, P. C., Li, S. D., Jiang, X. C., Eacho, P. I., Cao, G., and Paul, S. M. (2004) A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J. Neurochem. 88, 623-634.
110. Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., and Tontonoz, P. (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptoirs. Nat. Med. 9, 213-219.
111. Lefterov, I., Bookout, A., Wang, Z., Staufenbiel, M., Mangelsdorf, D., and Koldamova, R. (2007) Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment. Mol. Neurodeg. 2, 20.
112. Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M. E., Wilson, T. M., Rosenfeld, M. G., and Glass, C. K. (2007) Parallel SUMOylation-dependent pathways mediate gene- and signal-dependent transrepression by LXRs and PPARc. Mol. Cell. 25, 57-70.
113. Terasaka, N., Hiroshima, A., Ariga, A., Honzumi, S., Koieyama, T., Inaba, T., and Fujiwara, T. (2005) Liver X receptor agonists inhibit tissue factor expression in macrophages. FEBS J. 272, 1546-1556.
114. Fowler, A. J., Sheu, M. Y., Schmuth, M., Kao, J., Fluhr, J. W., Rhein, L., Collins, J. L., Willson, T. M., Mangelsdorf, D. J., Elias, P. M., and Feingold, K. R. (2003) Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J. Invest. Dermatol. 120, 246-255.
115. Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A., Collins, A. R., Laffitte, B. A., Chen, M., Noh, G., Goodman, J., Hagger, G. N., Tran, J., Tippin, T. K., Wang, X., Lusis, A. J., Hsueh, W. A., Law, R. E., Collins, J. L., Wilson, T. M., and Tontonoz, P. (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA. 99, 7604-7609.
116. Tangirala, R. K., Bischoff, E. D., Joseph, S. B., Wagner, B. L., Walczak, R., Laffitte, B. A., Daige, C. L., Thomas, D., Heyman, R. A., Mangelsdorf, D. J., Wang, X., Lusis, A. J., Tontonoz, P., and Schulman, I. G. (2002) Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA. 99, 11896-11901.
117. Zelcer, N., Khanlou, N., Clare, R., Jiang, Q., Reed-Geaghan, E. G., Landreth, G. E., Vinters, H. V., and Tontonoz, P. (2007) Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl. Acad. Sci. USA. 104, 10601-10606.
118. Riddell, D. R., Zhou, H., Comery, T. A., Kouranova, E., Lo, C. F., Warwick, H. K., Ring, R. H., Kirksey, Y., Aschmies, S., Xu, J., Kubek, K., Hirst, W. D., Gonzales, C., Chen, Y., Murphy, E., Leonard, S., Vasylyev, D., Oganesian, A., Martone, R. L., Pangalos, M. N., Reinhart, P. H., and Jacobsen, J. S. (2007) The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 34, 621-628.
119. Eckert, G. P., Vardanian, L., Rebeck, G. W., and Burns, M. P. (2007) Regulation of central nervous system cholesterol homeostasis by the liver X receptor agonist TO-901317. Neurosci. Lett. 423, 47-52.
120. Groot, P. H., Pearce, N. J., Yates, J. W., Stocker, C., Sauermelch, C., Doe, C. P., Willette, R. N., Olzinskiki, A., Peters, T., d'Epagnier, D., Morasco, K. O., Krawiec, J. A., Webb, C. L., Aravindham, K., Juker, B., Burgert, M., Ma, C., Marino, J. P., Collins, J. L., Macphee, C. H., Thompson, S. K., and Jaye, M. (2005) Synthetic LXR agonists increase LDL in CETP species. J. Lipid. Res. 46, 2182-2191